University of Miami School of Medicine, Miami, FL, McGill University, Montreal, Canadaand Healing Visions, St. Kitts, WIThe apparent ability of ibogaine to interrupt dependence on heroin and cocaine was first described in the early 1960s.Anecdotal accounts of the acute and long-term effects of ibogaine have included only a small series of case reports of opiateand cocaine addicts(Sheppard, 1994; Sisko, 1993; Alper et al., 1999) with observations provided for only 7, 4 and 14subjects, respectively. Thus, objective investigations of ibogaine's effects on craving for drugs and alcohol and on thesigns and symptoms of opiate withdrawal are not available. We have evaluated the safety and pharmacokinetics ofibogaine in the setting of an inpatient detoxification in over 400 patient volunteers assessed from 1996 to the present. Wehave attempted to collect data from this study using Food and Drug Administration guidelines for good clinical practices.Our clinical experience to date indicates that ibogaine has little toxicity in doses ranging from 1 to 14 mg/kg. Oraladministration of ibogaine to opiate-dependent individuals was associated with significant blockade of the characteristicopiate-withdrawal signs and symptoms. We have also examined whether ibogaine affects drug craving usingmultidimensional craving questionnaires for heroin and cocaine. To the extent that physical, psychological, and emotionalwell-being might impact their self-reports of craving during their course of stay, participants also completed standardizedquestionnaires about their health both before and after ibogaine treatment and at program discharge. To assess whether thebenefits of ibogaine on drug craving would persist outside of a controlled environment, one month follow-up data werealso collected. The results of ibogaine research conducted offshore indicates that ibogaine diminishes drug cravings andimproves mood. Ibogaine may an adjunct to brief intervention to help patients to reduce risky or hazardous drug andalcohol use. Ibogaine also motivates some drug-dependent patients to enter treatment with the goal of long-termabstinence. (Supported in part by the Addiction Research Fund).Offshore Investigations of the Non-Addictive Plant Alkaloid Ibogaine:1996 to 2004ibogainetreatmentwithdrawalopiateKeywordsPOSTE R SESSION I (Breakfast)Odd-numbered posters manned first hour;Even-numbered, second hourSet-up time begins Sunday 1:00 PMMust be removed by Monday 12:30 PM118Exhibition Hall8:00 - 10:00 AMBoard #:Monday, June 20, 20058:00 A.M. - 10:00 A.M.Author will attend:CPDD - 2005Orlando, Florida
--------------------------------------------------------------------------------
Page 2
L. Duque, C. Foord, B. Page and D.C. MashUniversity of Miami School of Medicine, Miami, FLIbogaine is an indole alkaloid contained in the root bark of tabenanthe iboga. Ibogaine has been used in equatorial Africa ina ritual context associated with the Fang Bwiti religion. In the present study, the psychological and subjective effects ofibogaine were evaluated in patients that met DSM-IV criteria for dependence on cocaine (N=30; 10 females, 20 males) oropiates (N=30; 11 females, 19 males). Subjects narrated their subjective experience. The interviewer trained in open-endedelicitation techniques, elicited descriptions of the acute drug effects. After the initial stimulus question, the interviewer useda guide questionnaire to assure that key areas of content received coverage in each interview. The areas of content focusedon sensations and perceptions, and interpretations of the experience. A content coding scheme was developed to catch keyelements from the narrative. Cross coding was repeated until the coders achieved greater than 90% agreement. TheHallucinogenic Rating Scale (HRS, Strassman et al., 1994) was used to assess acute subjective responses. There appearsto be common elements to the subjective experiences of drug-dependent patients treated with ibogaine. Ibogaine wasadministered as a single p.o. dose (10 mg/kg) with an acute onset of between 30 to 90 minutes. The duration of the active‘waking dream stage’ was from 4 to 8 hours depending on the subjects CYP2D6 genotype. All of the sixty subjectsreported the experience of visual phenomena from ibogaine. Approximately 40% (N=24) of the subjects reported that theyrelived their negative experiences that resulted from past drug abuse. Visions of previous early life events were reported by30% (N=1 of all participants, with 43% (N=26) reporting visions of self as a child. One-fourth of the subjects had avision of their own death and 10% reported death content with respect to others. Emotional and cognitive effects weremarked in these subjects. The unique subjective effects of ibogaine may be developed as an adjunct to brief intervention tomore effectively promote abstinence in drug-dependent populations.Structured Elicitation Narrative Reveals a Variety of Ibogaine ExperiencesIbogaine treatmentsubstance abuseKeywordsPOSTER SESSION I (Breakfast)Odd-numbered posters manned first hour;Even-numbered, second hourSet-up time begins Sunday 1:00 PMMust be removed by Monday 12:30 PM119Exhibition Hall8:00 - 10:00 AMBoard #:Monday, June 20, 20058:00 A.M. - 10:00 A.M.Author will attend:CPDD - 2005Orlando, Florida

You cannot post new topics in this forumYou cannot reply to topics in this forumYou cannot edit your posts in this forumYou cannot delete your posts in this forumYou cannot vote in polls in this forumYou cannot attach files in this forumYou cannot download files in this forum